A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)

BACKGROUND: Neoadjuvant dual human epidermal growth factor receptor (HER2) blockade with trastuzumab and pertuzumab plus paclitaxel leads to an overall pathologic complete response (pCR) rate of 46%. Dual HER2 blockade with ado-trastuzumab emtansine (T-DM1) and lapatinib plus nab-paclitaxel has show...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Breast Cancer Res
Main Authors: Patel, Tejal A., Ensor, Joe E., Creamer, Sarah L., Boone, Toniva, Rodriguez, Angel A., Niravath, Poly A., Darcourt, Jorge G., Meisel, Jane L., Li, Xiaoxian, Zhao, Jing, Kuhn, John G., Rosato, Roberto R., Qian, Wei, Belcheva, Anna, Schwartz, Mary R., Kaklamani, Virginia G., Chang, Jenny C.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6720931/
https://ncbi.nlm.nih.gov/pubmed/31477168
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-019-1186-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados